Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03978156 · ClinicalTrials.gov registry record · Phase 1
Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03978156 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 6 participants.
The verdict
NCT03978156, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is designed to address the feasibility of a randomized, double masked, cross-over study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
Interventions
- DRUG Dronabinol 2.5 MG
- DRUG Microcrystalline cellulose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-07-26 |
| Est. Completion | 2021-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03978156
The ClinicalTrials.gov registry entry for NCT03978156 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dronabinol 2.5 MG is the first listed.
NCT03978156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03978156 about?
NCT03978156 is a clinical study titled "Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease". This study is designed to address the feasibility of a randomized, double masked, cross-over study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
What is the current status of trial NCT03978156?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-07-26. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT03978156?
The interventions under investigation include: Dronabinol 2.5 MG (DRUG), Microcrystalline cellulose (DRUG).
Who is sponsoring clinical trial NCT03978156?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.